What's in CT Glaucoma Associates's pipeline?

CT Glaucoma Associates has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with CT Glaucoma Associates's portfolio?

Top competitors by shared drug class: Pharmaceutical Research Network.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ct-glaucoma-associates.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

CT Glaucoma Associates — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CT Glaucoma Associates pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
dorzolamide/timolol	dorzolamide/timolol	marketed	Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination	Carbonic anhydrase II / Beta-adrenergic receptors (β1 and β2)	Ophthalmology

Therapeutic area mix

Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pharmaceutical Research Network · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CT Glaucoma Associates:

Cite this brief

Drug Landscape (2026). CT Glaucoma Associates — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ct-glaucoma-associates. Accessed 2026-06-10.